← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA6838.9x13.3x20.3x
EV / LTM revenue9890.9x1.9x3.7x
Premium to unaffected price86421%32%51%
Premium to 30-day VWAP14015%32%47%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
0611212009: 9 deals, 2 clean on every measure200992010: 121 deals, 30 clean on every measure20101212011: 107 deals, 70 clean on every measure20111072012: 100 deals, 93 clean on every measure20121002013: 104 deals, 92 clean on every measure20131042014: 68 deals, 59 clean on every measure2014682015: 88 deals, 81 clean on every measure2015882016: 111 deals, 103 clean on every measure20161112017: 98 deals, 90 clean on every measure2017982018: 101 deals, 93 clean on every measure20181012019: 95 deals, 90 clean on every measure2019952020: 46 deals, 44 clean on every measure2020462021: 97 deals, 85 clean on every measure2021972022: 81 deals, 77 clean on every measure2022812023: 77 deals, 62 clean on every measure2023772024: 92 deals, 82 clean on every measure2024922025: 97 deals, 84 clean on every measure2025972026: 48 deals, 41 clean on every measure202648
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Technology: 18.5x median across 134 dealsTechnology18.5xn=134Healthcare: 18.4x median across 69 dealsHealthcare18.4xn=69Real Estate: 16.7x median across 39 dealsReal Estate16.7xn=39Business Services: 14.4x median across 56 dealsBusiness Services14.4xn=56Industrials: 13.5x median across 100 dealsIndustrials13.5xn=100Financials: 13.4x median across 18 dealsFinancials13.4xn=18Utilities: 12.4x median across 44 dealsUtilities12.4xn=44Other: 10.9x median across 25 dealsOther10.9xn=25Consumer & Retail: 10.5x median across 112 dealsConsumer & Retail10.5xn=112Materials: 9.9x median across 28 dealsMaterials9.9xn=28Energy: 8.9x median across 26 dealsEnergy8.9xn=26Media & Telecom: 8.8x median across 32 dealsMedia & Telecom8.8xn=32
Deals by sector
Technology: 318 dealsTechnology318Healthcare: 243 dealsHealthcare243Industrials: 180 dealsIndustrials180Consumer & Retail: 174 dealsConsumer & Retail174Financials: 163 dealsFinancials163Business Services: 109 dealsBusiness Services109Real Estate: 87 dealsReal Estate87Utilities: 60 dealsUtilities60Energy: 56 dealsEnergy56Media & Telecom: 55 dealsMedia & Telecom55Materials: 51 dealsMaterials51Other: 44 dealsOther44
Deals by buyer type
Financial sponsor: 43 dealsFinancial sponsor43Strategic: 871 dealsStrategic871Management / founder: 0 dealsManagement / founder0Controlling holder: 0 dealsControlling holder0Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 626 dealsUnclassified626
Deals by enterprise value
Under $250m: 503 dealsUnder $250m503$250m to $1bn: 372 deals$250m to $1bn372$1bn to $5bn: 448 deals$1bn to $5bn448$5bn to $20bn: 181 deals$5bn to $20bn181Over $20bn: 24 dealsOver $20bn24Not computed: 12 dealsNot computed12
Deals by industry code
Business Services & Software: 277 dealsBusiness Services & Sof…277Chemicals, Pharmaceuticals & Allied Products: 149 dealsChemicals, Pharmaceutic…149Electronics & Electrical Equipment: 119 dealsElectronics & Electrica…119Instruments, Medical Devices & Optical Goods: 95 dealsInstruments, Medical De…95Holding & Other Investment Offices: 67 dealsHolding & Other Investm…67Electric, Gas & Sanitary Services: 60 dealsElectric, Gas & Sanitar…60Depository Institutions: 57 dealsDepository Institutions57Industrial Machinery & Computers: 56 dealsIndustrial Machinery & …56Insurance Carriers: 50 dealsInsurance Carriers50Health Services: 50 dealsHealth Services50
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Seres Therapeutics, Inc.
2024-08-26 (filed) · Public merger · $1.05 a share
Held out of the multiples: EV / LTM revenue 495.2x above 60x
Not named in the filing
Unclassified
Healthcare$198mn.a.495.3x
n.a.
10% to VWAP
DEFM14A
All cash
Terran Orbital Corp
2024-08-15 · Public merger · $0.25 a share
Not named in the filing
Unclassified
Industrials$221mn.a.1.7x
n.a.
DEFM14A
All cash
Kellanova
2024-08-13 · Public merger · $83.50 a share
Acquiror 10VB8, LLC
Strategic
Consumer & Retail$34bn18.7x3.0x
n.a.
44% to VWAP
DEFM14A
All cash
SBC Medical Group Holdings Inc
2024-08-12 (filed) · Public merger · $11.50 a share
Mehana Capital, LLC
Financial sponsor
Healthcare$2.3bnn.a.n.a.
n.a.
DEFM14A
All cash
Iteris, Inc.
2024-08-08 · Public merger · $7.20 a share
Held out of the multiples: EV / LTM EBITDA 168.8x outside 1x to 75x
Almaviva S.p.A.
Strategic
Technology$287m168.8x1.6x
68%
DEFM14A
All cash
Gse Systems Inc
2024-08-08 · Public merger · $4.10 a share
Nuclear Engineering Holdings LLC
Strategic
Technology$12mn.a.0.3x
50%
15% to VWAP
DEFM14A
All cash
Gse Systems Inc
2024-08-08 · Public merger · $4.10 a share
Nuclear Engineering Holdings LLC
Strategic
Technology$12mn.a.0.3x
50%
15% to VWAP
DEFM14A
All cash
PetIQ, Inc.
2024-08-07 · Public merger · $31.00 a share
Not named in the filing
Unclassified
Energy$1.3bn14.3x1.1x
51%
41% to VWAP
DEFM14A
All cash
PetIQ, Inc.
2024-08-07 · Public merger · $31.00 a share
Not named in the filing
Unclassified
Energy$1.3bn14.3x1.1x
51%
41% to VWAP
DEFM14A
All cash
Clover Leaf Capital Corp.
2024-07-31 (filed) · Public merger · $10.00 a share
Yntegra Capital Investments LLC
Financial sponsor
Consumer & Retail$195mn.a.n.a.
n.a.
DEFM14A
All cash
Everi Holdings Inc.
2024-07-26 · Public merger · $14.25 a share
International Game Technology PLC
Strategic
Consumer & Retail$1.9bn9.3x2.5x
56%
66% to VWAP
DEFM14A
All cash
Instructure Holdings, Inc.
2024-07-25 · Public merger · $23.60 a share
Held out of the multiples: EV / LTM EBITDA 1675.1x outside 1x to 75x
Icon Parent Inc.
Unclassified
Technology$4.5bn1675.1x7.6x
21%
DEFM14C
All cash
Tellurian Inc. /de/
2024-07-21 · Public merger · $1.00 a share
Woodside Energy Holdings LLC
Strategic
Energy$951mn.a.11.4x
n.a.
DEFM14A
All cash
Augmedix, Inc.
2024-07-19 · Public merger · $2.35 a share
Commure, Inc.
Strategic
Business Services$87mn.a.1.7x
n.a.
169% to VWAP
DEFM14A
All cash
Galaxy Gaming, Inc.
2024-07-18 · Public merger · $3.20 a share
Evolution Malta Holding Limited
Strategic
Consumer & Retail$115m12.3x3.9x
124%
DEFM14A
All cash
Chuy'S Holdings, Inc.
2024-07-17 · Public merger · $37.50 a share
Darden Restaurants, Inc.
Strategic
Consumer & Retail$592m11.7x1.3x
48%
6% to VWAP
DEFM14A
All cash
Surmodics Inc
2024-07-08 (filed) · Public merger · $43.00 a share
Held out of the multiples: EV / LTM EBITDA 503.8x outside 1x to 75x
Not named in the filing
Unclassified
Healthcare$605m503.8x5.0x
n.a.
DEFM14A
All cash
Desktop Metal, Inc.
2024-07-02 · Public merger · $5.50 a share
Nano Dimension Ltd., Inc.
Strategic
Industrials$1.8bnn.a.10.2x
27%
DEFM14A
All cash
Agile Therapeutics Inc
2024-06-25 · Public merger · $1.52 a share
Insud Pharma
Strategic
Healthcare$11mn.a.0.5x
n.a.
DEFM14A
All cash
Alimera Sciences Inc
2024-06-21 · Public merger · $5.50 a share
ANI Pharmaceuticals, Inc.
Strategic
Healthcare$274m26.8x3.0x
n.a.
82% to VWAP
DEFM14A
All cash
Silk Road Medical Inc
2024-06-17 · Public merger · $27.50 a share
Boston Scientific Corporation, Inc.
Strategic
Healthcare$986mn.a.5.3x
n.a.
DEFM14A
All cash
Aaron's Company, Inc.
2024-06-16 · Public merger · $10.10 a share
IQVentures Holdings, LLC
Strategic
Business Services$481m6.2x0.2x
34%
DEFM14A
All cash
ICC Holdings, Inc.
2024-06-08 · Public merger · $23.50 a share
Mutual Capital Holdings, Inc.
Financial sponsor
Financials$82mn.a.0.9x
n.a.
48% to VWAP
DEFM14A
All cash
First Financial Northwest, Inc.
2024-06-07 (filed) · Public merger · $23.59 a share
Not named in the filing
Unclassified
Financials$167mn.a.57.7x
n.a.
DEFM14A
All cash
Asensus Surgical, Inc.
2024-06-06 · Public merger · $0.35 a share
KARL STORZ Endoscopy-America, Inc.
Strategic
Healthcare$87mn.a.10.0x
52%
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More